Compare Indonesia Energy Corporation Limited (INDO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Travere Therapeutics Inc. Common Stock — how do they compare? Indonesia Energy Corporation Limited trades at $2.66 (market cap $42.31M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 115.3× Indonesia Energy Corporation Limited's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| INDO | TVTX | |
|---|---|---|
Market Cap | $42.31M | $4.88B |
Volume | 193,916 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $6.74 | $67.52 |
52-Week Low | $2.49 | $26.79 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $37.25M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.75 with minimal daily movement (+0.36%). The stock shows bearish technical signals despite unanimous analyst buy ratings. Fundamentally, the company faces significant challenges with negative profit margins (-152.72% net income margin) and consistent quarterly losses, though recent oil discoveries at the K-29 well provide operational optimism. Cash flow remains dependent on financing activities to offset negative operational cash flow.
While analyst consensus remains bullish with 100% buy ratings, the stock presents high-risk exposure due to persistent unprofitability and negative cash generation. The company's exploration success offers potential upside, but investors face substantial execution risk and financial instability in the near term.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
